Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
  6. Scopus by Title (Ref)

IJ Pharmaceutical Research

Home
Current IssueAll IssuesIn PressAccepted Manuscripts
SearchInstructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis

- Fukuda N. , et al.

2. Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials

- Xiao Z. , et al.

3. Beneficial effects and therapeutic promises of diterpenes on respiratory system

- Islam M.T. , et al.

4. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer

- Subhani S. , et al.

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.